FDG PET imaging measures glucose uptake in the brain. It has long served as a proxy for neuronal health—but is it? In the October 13 Science Translational Medicine, researchers led by Christian Haass ...
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell ...
Expert Rev Anticancer Ther. 2009;9(1):75-96. Based on the available data, FDG-PET alone appears to be of limited use in differentiating tumors of low malignant potential from benign tumors and ovarian ...
Oxaliplatin, irinotecan, bevacizumab followed by docetaxel, bevacizumab in inoperable gastric cancer: Final efficacy results of a multicenter phase II trial (AGMT Gastric-3) of the arbeitsgemeinschaft ...
Reston, VA—A new PET radiotracer can differentiate diseased tissues from healthy tissues based on fructose metabolism, according to new research published in the March issue of The Journal of Nuclear ...
Brain PET is a powerful imaging modality that directly reflects cerebral metabolic activity, making it an essential tool for ...
Total-body dynamic 18F-FDG PET imaging with the uEXPLORER scanner allows us to monitor the spatiotemporal distribution of glucose concentration in metastatic tumors in the entire body (a). As compared ...
Fluorodeoxyglucose (FDG) has proven benefits as a positron emission tomography (PET) radiopharmaceutical in oncology. However, it has limitations in the assessment of certain tumours, above all (but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results